Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer Expands Further Into Generics

by Marc S. Reisch
May 25, 2009 | A version of this story appeared in Volume 87, Issue 21

Pfizer continues to expand its Established Products business unit, launched last year, with two new agreements. The first expands its license agreements with India-based Aurobindo Pharma, and the second entails a new agreement with India-based Claris Lifesciences. Under the agreement with Aurobindo, Pfizer has acquired rights to 55 oral dose products and five injectables in more than 70 emerging-market countries. Pfizer says it also expanded its agreement with Aurobindo in developed markets, adding products in the U.S. and Europe. The deal with Claris gives Pfizer rights to 15 injectable medicines after they have lost market exclusivity.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.